These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 266212)

  • 21. Bepridil as an antisickling agent: membrane internalization and cell rigidity.
    Johnson RM; Acquaye C; Féo C; Sarnaik S
    Am J Hematol; 1994 Aug; 46(4):310-8. PubMed ID: 8037182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of beta-adrenergic blockers on the sickling phenomenon.
    Ohnishi ST; Hashimoto K; Sato T; Devlin MT; Singer M
    Can J Physiol Pharmacol; 1982 Feb; 60(2):148-53. PubMed ID: 6123378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sickle cell anemia and antisickling agents then and now.
    Mehanna AS
    Curr Med Chem; 2001 Feb; 8(2):79-88. PubMed ID: 11172667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
    Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T
    Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of oxygen unloading from sickle erythrocytes.
    Makhijani VB; Cokelet GR; Clark A
    Biophys J; 1990 Oct; 58(4):1025-52. PubMed ID: 2248988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rheological assessment of antisickling effects of pyridoxine and pyridoxal.
    Kuranstin-Mills J; Lessin LS
    Blood Cells; 1982; 8(2):315-28. PubMed ID: 7159755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sickle cell anemia and the affinity of the blood for oxygen].
    Pocidalo JJ; Sinet M
    C R Seances Soc Biol Fil; 1979; 173(2):303-13. PubMed ID: 159755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.
    Li Q; Henry ER; Hofrichter J; Smith JF; Cellmer T; Dunkelberger EB; Metaferia BB; Jones-Straehle S; Boutom S; Christoph GW; Wakefield TH; Link ME; Staton D; Vass ER; Miller JL; Hsieh MM; Tisdale JF; Eaton WA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E689-E696. PubMed ID: 28096387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
    Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease.
    Keipert PE;
    Adv Exp Med Biol; 2016; 923():23-29. PubMed ID: 27526120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sickling as a function of oxygen delivery: effect of simulated transfusions of stored, fresh and inositol-hexaphosphate-loaded (low affinity) red cells.
    Kumpati J; Franco RS; Weiner M; Martelo OJ
    Blood Cells; 1982; 8(2):263-72. PubMed ID: 7159750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
    Franklin IM; Huehns ER; Rosemeyer MA
    Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of red cell sickling. Effects of varying pH and of increasing intracellular hemoglobin concentration by osmotic shrinkage.
    Bookchin RM; Balazs T; Landau LC
    J Lab Clin Med; 1976 Apr; 87(4):597-616. PubMed ID: 5563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM
    ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl adipimidate: a new antisickling agent.
    Lubin BH; Pena V; Mentzer WC; Bymun E; Bradley TB; Packer L
    Proc Natl Acad Sci U S A; 1975 Jan; 72(1):43-6. PubMed ID: 1054514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
    J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl)fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site.
    Chatterjee R; Iwai Y; Walder RY; Walder JA
    J Biol Chem; 1984 Dec; 259(23):14863-73. PubMed ID: 6501320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.